Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy
- PMID: 40016555
- PMCID: PMC11868359
- DOI: 10.1007/s00330-024-11343-w
Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy
Abstract
Objective: To evaluate the success and complications of thermal ablation (TA) based on the voluntary, prospective registry of the German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) with 303 participating centers from Germany, Austria, and Switzerland.
Materials and methods: Registry data from 2018 until 2023 of 1102 patients with small renal tumors (age: 72.5 ± 11.6 years; female: 33.6%, 370/1102) were analyzed. Hospitals with ≥ 20 TAs were considered high-volume centers. Technical success and complication rates between different parameters were compared using the chi-square or Fisher's exact test, p < 0.05 was considered statistically significant.
Results: Patients were most frequently treated with radiofrequency ablation (RFA, 43.6%, 481/1102), then microwave ablation (MWA, 41.9%, 462/1102) or cryoablation (13.3%, 147/1102). Technical success for heat-based TA (RFA&MWA) was 94.3% (893/947), for cryoablation 97.3% (143/147). RFA&MWA was significantly more successful in lesions ≤ 3 cm (96.1%, 567/590) compared to 3-4 cm lesions (89.8%, 97/108; p = 0.005). In patients treated with cryoablation, no significant differences between sizes could be found (≤ 3 cm: 97.9%, 94/96; 3-4 cm: 85.7%, 12/14; p = 0.078). Complication rate was significantly higher in RFA&MWA of lesions 3-4 cm compared to ≤ 3 cm (≤ 3 cm: 3.9%, 23/590; 3-4 cm: 11.1%, 12/108, p = 0.002), while no significant differences were seen regarding cryoablation (≤ 3 cm: 1.0%, 1/96; 3-4 cm: 0.0%, 0/14; p = 1.000).
Conclusions: In this exploratory analysis of the DeGIR registry, percutaneous TA of small renal masses is technically feasible with low complication rates. Heat-based TAs seem to have lower success rates and higher complication rates in larger tumors. Cryoablation could potentially be a safe alternative for 3- to 4-cm-sized tumors.
Key points: Question How effective is renal thermal ablation (TA) in terms of treatment success and complication rates? Findings In contrast to cryoablation, heat-based thermal ablation has lower success and higher complication rates in tumors measuring 3-4 cm compared to tumors < 3 cm. Clinical relevance Thermal ablation is not influenced by the need for additional techniques such as cooling, protective organ displacement, or temporary vessel occlusion. For small renal tumors, TA is an effective and safe treatment option. Cryoablation could be beneficial in larger tumors.
Keywords: Cryoablation; Kidney; Microwave ablation; Radiofrequency ablation.
© 2025. The Author(s).
Conflict of interest statement
Compliance with ethical standards. Guarantor: The scientific guarantor of this publication is Benedikt M. Schaarschmidt. Conflict of interest: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. Statistics and biometry: No complex statistical methods were necessary for this paper. Informed consent: Written informed consent was waived by the Institutional Review Board. Ethical approval: Institutional Review Board approval was obtained from the local ethics committee of the University Duisburg-Essen (Approval number: 23-11352-BO, date of approval: 25.07.2023). Study subjects or cohorts overlap: No study subjects or cohorts have been previously reported. Methodology: Retrospective Observational Multicenter study
Figures
Comment in
-
Not just a picture of a changing treatment landscape: what registry data from Germany add to our knowledge about thermal ablation for kidney tumors.Eur Radiol. 2025 Sep;35(9):5801-5803. doi: 10.1007/s00330-025-11415-5. Epub 2025 Feb 28. Eur Radiol. 2025. PMID: 40021502 Free PMC article. No abstract available.
References
-
- Uroweb (2024) EAU guidelines on renal cell cancer (update 2024). European Association of Urology. https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/introduction. Accessed 11 May 2024
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
